Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.81 |
| ▸ | SLC5A1 | P13866 | 13/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037900 | 1.00 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL10822009 | 0.99 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL2583297 | 0.91 | SLC5A2 (0.80) | SLC5A2SLC5A1 | |
| SCHEMBL2576286 | 0.91 | SLC5A2 (0.80) | SLC5A2SLC5A1 | |
| SCHEMBL4356542 | 0.90 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL2582707 | 0.90 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL2577417 | 0.90 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL4350700 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2577336 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2578932 | 0.90 | SLC5A2 (0.78) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | claimed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | claimed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | claimed |
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20110059910-A1 | Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-7820804-B2 | Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | Sanofi-Aventia Deutschland GmbH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20070197623-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20040259819-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | UGGT1, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | SLC5A2 3/4885SLC5A1 1/4885 |
| US-20110059910-A1 | Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20040259819-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A1, UGGT1, SLC5A2 | SLC5A2 3/4885SLC5A1 1/4885 |
| US-20070197623-A1 | NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | DPP4, UGGT1, SLC5A2 | SLC5A2 3/4885SLC5A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.